0
0This study examines the therapeutic efficacy of RAS(ON) multi-selective inhibitors—specifically daraxonrasib and the compound RMC-7977—in treating KRAS-mutant cholangiocarcinoma (CCA). Through extensive testing in cell-derived and patient-derived models, researchers demonstrated that these inhibitors significantly suppress tumor growth and improve survival rates by targeting the active, GTP-bound state of RAS. The findings highlight that RAS pathway reactivation, through mechanisms like gene amplification and MYC overexpression, serves as the primary driver of drug resistance. Furthermore, the study establishes a translational roadmap showing that combining RAS inhibitors with standard chemotherapy yields superior results compared to monotherapy. Clinical evidence is also presented through objective responses in human patients, suggesting a potential shift in the treatment paradigm for this aggressive biliary tract cancer. Ultimately, the data confirms that KRAS-mutant CCA is highly dependent on RAS signaling, making it a viable target for next-generation precision medicine.
References:
Entrialgo-Cadierno R, Morali K, Feliu I, et al. Anticancer activity of RAS-GTP inhibition in cholangiocarcinoma[J]. Cancer Cell, 2026.
